Division of Hematology News

Alexis A. Thompson, MD, MPH, chief, Division of Hematology, and the Elias Schwartz MD Endowed Chair in Hematology at CHOP, has been recognized for her leadership in sickle cell disease (SCD) treatment and research.

CHOP announced that its first patients outside of clinical trials have begun the treatment process for the newly FDA approved sickle cell gene therapies.

Researchers at CHOP announced the results of a new study offering insights into the development of next-generation gene therapies to treat hemophilia A.

Researchers at Children’s Hospital of Philadelphia (CHOP) announced a significant breakthrough in understanding chemotherapy resistance in high-risk neuroblastoma, a common and potentially deadly childhood cancer arising within the peripheral nervous system.

The life and legacy of the late Dr. Kwaku Ohene-Frempong was celebrated by family, friends and colleagues at his portrait unveiling ceremony on CHOP’s campus on June 20.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a new model that offers a potential platform for developing novel therapies to treat Alpha Thalassemia (AT), a severe blood disorder. The findings were published in the journal Blood.

Earlier this month, Children’s Hospital of Philadelphia (CHOP) hosted the Cure Sickle Cell Walk & Family Fun Day presented by West Pharmaceutical Services at Citizens Bank Park raising more than $256,000 (and counting!) to support sickle cell warriors.

Innovative model highlights bone marrow transplantation without toxic side effects.

New model and vector may hold the keys to transforming the lives of XLSA patients.

In a landmark study, an international consortium led by researchers at CHOP published the final results of a key clinical trial of the gene therapy CASGEVY for the treatment of sickle cell disease.